Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline

/in

Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited (ASX: DXB) Mission will receive up to US$292 million in upfront and milestone payments, plus up to double-digit tiered royalties on global net sales Divestment validates Mission’s USP30 platform and provides non-dilutive capital […]

Read more

Simris Group AB Appoints ADC Expert Professor Andreas Pahl as Chief Executive Officer of its Subsidiary Simris Biologics GmbH

/in

Simris Group AB (SIMRIS B) today announced the appointment of Professor Andreas Pahl as Chief Executive Officer of Simris Biologics GmbH, its wholly owned subsidiary based in Berlin, Germany. Professor Pahl will begin his assignment immediately. Simris Biologics develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies. Professor Pahl will lead the advancement of […]

Read more

Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company

/in

San Francisco, California – Yavne, Israel – July 14th, 2026 – Genopore, the next-generation proteomics company developing the first semiconductor based optical nanopore technology platform with AI/ML analysis for direct single protein molecule identification and digital quantification, today announced the appointment of life science leader Rey Mali as its new Chief Executive Officer, with immediate […]

Read more

Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology

/in

Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of disease from human genetics Oxford, UK, 14 July 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’) – a pioneering biotechnology company unlocking the therapeutic potential of the regulatory genome through its proprietary 3D genomics platform – […]

Read more

ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board

/in

Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board Member Appointments build the financial and […]

Read more
© Optimum Strategic Communications.